



**TRIMURTHI LIMITED**

Dated: 24-11-2023

Dt: 24/11/23

To

BSE Limited

P.J. Towers, Dalal Street,

Mumbai-400001.

**TRIMURTHI LIMITED**

#5-8-354, Office No. 1106, Ratna Block

Raghav Ratna Towers, Chirag Ali Lane, Abids

Hyderabad, Telangana - 500001 | Tel: 040 23314435

Email: info@trimurthidrugs.com

Website: www.trimurthidrugs.com

CIN No. L67120TG1994PLC018956

Dear Sir/Madam,

Sub: Consolidated Financial Results for the Quarter ended 31-12-2022.

Unit: Trimurthi Limited.

As Advised by BSE Limited we are enclosing Consolidated Financial Results for the Quarter ended 31-12-2022. even though it is not applicable to the Company.

Thanking You,

For Trimurthi Limited

*Ravi Bhangadia*

Ravi Bhangadia

Chairman

DIN: 03434400

Encl: as above





**TRIMURTHI LIMITED**

## TRIMURTHI LIMITED

#5-8-354, Office No. 1106, Ratna Block  
Raghav Ratna Towers, Chirag Ali Lane, Abids  
Hyderabad, Telangana - 500001 | Tel: 040 23314435  
Email: info@trimurthidrugs.com  
Website: www.trimurthidrugs.com  
CIN No. L67120TG1994PLC018956

**TRIMURTHI LIMITED**  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.  
**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS**  
**FOR THE QUARTER III AND NINE MONTHS ENDED 31ST DECEMBER 2022**

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
<b>1. INCOME</b>						
INCOME FROM OPERATIONS	(206.18)	124.09	111.13	53.88	792.14	860.85
OTHER INCOME	17.00	5.69	6.65	28.32	46.19	55.41
<b>TOTAL INCOME</b>	<b>(189.18)</b>	<b>129.78</b>	<b>117.78</b>	<b>82.20</b>	<b>838.33</b>	<b>916.26</b>
<b>2. EXPENSES</b>						
PURCHASES	(147.70)	106.87	95.98	71.41	724.12	826.03
COST OF MATERIALS CONSUMED	(14.29)	3.63	6.74		41.56	26.77
MANUFACTURING EXPENSES	-	-	(1.66)		42.28	0.55
INCREASE/(DECREASE) IN STOCK IN TRADE	(24.74)	0.75	33.93	(24.19)	(57.53)	(28.37)
RENT	(4.54)	5.74	0.80	1.20	3.60	8.20
EMPLOYEE BENEFITS EXPENSE	(13.12)	19.70	16.49	20.71	51.63	71.98
FINANCE COSTS	-	-	-		0.06	
DEPRECIATION AND AMORTISATION EXPENSES	0.56	1.99	4.48	4.21	12.82	10.20
OTHER EXPENSES	(2.60)	4.91	51.87	16.12	80.65	213.06
<b>TOTAL EXPENSES</b>	<b>(206.43)</b>	<b>143.59</b>	<b>208.63</b>	<b>89.46</b>	<b>899.19</b>	<b>1,128.41</b>
<b>3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2)</b>	<b>17.25</b>	<b>(13.81)</b>	<b>(90.85)</b>	<b>(7.26)</b>	<b>(60.86)</b>	<b>(212.16)</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>						
<b>5. PROFIT/LOSS BEFORE TAX &amp; SHARE IN ASSOCIATE(3-4)</b>	<b>17.25</b>	<b>(13.81)</b>	<b>(90.85)</b>	<b>(7.26)</b>	<b>(60.86)</b>	<b>(212.16)</b>
<b>6. SHARE OF PROFIT/LOSS OF ASSOCIATE</b>	-	(1.27)	(4.09)	0.55	5.29	8.67
<b>7. PROFIT/(LOSS) BEFORE TAX (3-4)</b>	<b>17.25</b>	<b>(15.08)</b>	<b>(94.94)</b>	<b>(6.71)</b>	<b>(55.57)</b>	<b>(203.49)</b>
<b>8. TAX EXPENSES</b>	<b>0.53</b>	<b>0.27</b>	<b>(21.33)</b>	<b>(0.10)</b>	<b>(9.38)</b>	<b>(0.78)</b>
-CURRENT TAX	-	-	(9.94)			
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-				
-DEFERRED TAX (NET)	0.53	0.27	(11.39)	(0.10)	(9.38)	(0.78)
<b>9. NET PROFIT/(LOSS) FOR THE PERIOD FROM CONTINUING OPERATIONS (7-8)</b>	<b>17.78</b>	<b>(15.35)</b>	<b>(73.61)</b>	<b>(6.81)</b>	<b>(46.19)</b>	<b>(202.71)</b>
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>						
<b>11. TAX EXPENSES OF DISCONTINUED OPERATIONS</b>						
<b>12. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (10-11)</b>						
<b>13. PROFIT/(LOSS) FOR THE PERIOD (9+12)</b>	<b>17.78</b>	<b>(15.35)</b>	<b>(73.61)</b>	<b>(6.81)</b>	<b>(46.19)</b>	<b>(202.71)</b>
<b>14. OTHER COMPREHENSIVE INCOME</b>						
LOSS						
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
<b>15. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>17.78</b>	<b>(15.35)</b>	<b>(73.61)</b>	<b>(6.81)</b>	<b>(46.19)</b>	<b>(202.71)</b>
<b>16. MINORITY INTEREST</b>	-	(2.46)	(11.47)	-	(1.19)	(22.69)
<b>17. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD AFTER MINORITY INTEREST(15-16)</b>	<b>17.78</b>	<b>(12.89)</b>	<b>(62.14)</b>	<b>(6.81)</b>	<b>(45.00)</b>	<b>(180.02)</b>
<b>18. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :</b>						
(i) BASIC	0.22	(0.19)	(0.77)	(0.08)	(0.56)	(2.22)
(ii) DILUTED	0.22	(0.19)	(0.77)	(0.08)	(0.56)	(2.22)
<b>19. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :</b>						
(i) BASIC	-	-	-	-	-	-
(ii) DILUTED	-	-	-	-	-	-
<b>20. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :</b>						
(i) BASIC	0.22	(0.19)	(0.77)	(0.08)	(0.56)	(2.22)
(ii) DILUTED	0.22	(0.19)	(0.77)	(0.08)	(0.56)	(2.22)

Ravi Raghav  




# TRIMURTHI LIMITED

TRIMURTHI LIMITED

## TRIMURTHI LIMITED

#5-8-354, Office No. 1106, Ratna Block  
Raghav Ratna Towers, Chirag Ali Lane, Abids  
Hyderabad, Telangana - 500001 | Tel: 040 23314435  
Email: info@trimurthidrugs.com  
Website: www.trimurthidrugs.com  
CIN No. L67120TG1994PLC018956

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
<b>A. PARTICULARS OF SHARE HOLDING</b>						
1. Public Share Holding						
- Number of Shares	2679267	2900600	2900600	2679267	2900600	2900600
- Percentage of shareholding	33.08%	35.81%	35.81%	33.08%	35.81%	35.81%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered						
- No of Equity Shares	5420733	5199400	5199400	5420733	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	66.92%	64.19%	64.19%	66.92%	64.19%	64.19%

Particulars	3 Months Ended ( 31/12/2022)
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

## TRIMURTHI LIMITED


### Segment Reporting

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
<b>1. Segment Revenue</b>						
a. Pharma Business	-244.74	121.98	100.94	6.73	633.47	785.46
b. Financial Services	5.93	5.66	6.65	17.23	20.80	29.78
c. Investments	11.07	0.02	(0.02)	11.09	25.38	25.39
d. Trading in Shares	38.56	2.11	9.37	47.15	77.18	75.62
e. Foods	-	-	0.84	-	81.50	-
<b>Total</b>	<b>-189.19</b>	<b>129.78</b>	<b>117.78</b>	<b>82.20</b>	<b>838.33</b>	<b>916.25</b>
Less: Inter Segment Revenue						
<b>Net Sales/ Income From Operations</b>	<b>-189.19</b>	<b>129.78</b>	<b>117.78</b>	<b>82.20</b>	<b>838.33</b>	<b>916.25</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	9.98	-2.01	(34.70)	(0.46)	(3.88)	(3.27)
b. Financial Services	5.93	5.66	6.65	17.23	20.74	15.39
c. Investments	11.07	0.02	(0.02)	11.09	25.38	0.55
d. Trading in Shares	-9.73	(17.48)	(14.63)	(35.12)	(39.82)	(204.65)
e. Foods	-	-	(48.17)	-	(63.28)	(20.18)
<b>Total</b>	<b>17.25</b>	<b>(13.80)</b>	<b>(90.87)</b>	<b>(7.26)</b>	<b>(60.86)</b>	<b>(212.16)</b>
Less:						
i. Interest						
ii. Other Un-allocable expenses net off						
iii. Un-allocable Income						
<b>Total Profit Before Tax</b>	<b>17.25</b>	<b>(13.80)</b>	<b>(90.87)</b>	<b>(7.26)</b>	<b>(60.86)</b>	<b>(212.16)</b>
<b>3. Capital Employed</b>						
a. Pharma Business	40.18	148.94	140.42	40.18	140.42	77.55
b. Financial Services	104.83	17.59	129.12	104.83	129.12	255.08
c. Investments	203.75	216.58	32.29	203.75	32.29	35.06
d. Trading in Shares	368.75	337.21	326.30	368.75	326.30	298.64
e. Foods	-	-	13.34	-	13.34	74.07
<b>Total</b>	<b>717.51</b>	<b>720.33</b>	<b>641.47</b>	<b>717.51</b>	<b>641.47</b>	<b>740.40</b>

### Notes:

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 24-11-2023
- The above consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- The results are also available on the website of the Company
- During this quarter under review, the company has sold its subsidiary Trimurthi Pharmaceuticals (INDIA) Private Limited, so the comparative figures for the previous quarter are not comparable.

Place : Hyderabad  
Date : 24-11-2023







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
FAX : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to  
The Board of Directors  
Trimurthi Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of **Trimurthi Limited** (the "Holding Company") its Associate for the quarter ended 31<sup>st</sup> December, 2022 and for the period from 01<sup>st</sup> April 2022 to 31<sup>st</sup> December 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
FAX : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Emphasis of Matter Paragraph:**

As disclosed in Note no. 5 to the financial results, During this quarter under review the company has sold its wholly owned subsidiary Trimurthi pharmaceuticals (India) private limited.

Our opinion is not modified in respect of the above matter.


The Statement includes the results of the following entities:

**1. Curova India LLP - Associate**

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

Associate, whose interim Financial results reflect Group's share of total net profit of Rs. Nil for the quarter ended 31 December, 2022 and Rs. 55,221/-for the period from 01 April 2022 to 31 December 2022 as considered in the consolidated Financial Results. These unaudited interim Financial Statements have been furnished to us by the management and our conclusion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on such unaudited interim Financial Statements/financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these interim Financial results/financial information are not material to the Group.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
FAX : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com.  
Website : www.p murali.com


Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management

For P. Murali & Co.

Chartered Accountants

FRN: 007257S

  
A. Krishna Rao  
Partner  
M.No. 020085  
UDIN: 23020085BGQYQQ9816



Place: Hyderabad

Date: 24-11-2023